Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HuMAB companies -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (297)	12/21/2001 6:42:57 PM
From: Miljenko Zuanic	Respond to of 1022

Tuck, In PM you asked me about PCOP and Eos deal. Yes, I did choused PCOP as my 2001 pick, but it was great disappointment so far. I was expecting break-up software business this year, and focus on proprietary drugs and targets. Also, progress with collaborators, especially with Roche on MC-R4 agonist. Very little moved forward. I do not know much about Eos and what they are doing, but in my view it is not in synergy with what PCOP should do. If they do need help on target identification and characterization, collaboration should be sufficient, not merge (which is expensive for PCOP). Going forward, can PCOP re-discover itself? Maybe! Mollica is good and experienced guy, but for successful business one need good team works, not single person efforts. Miljenko